Literature DB >> 27474150

FLIP: A Targetable Mediator of Resistance to Radiation in Non-Small Cell Lung Cancer.

Kylie A McLaughlin1, Zsuzsanna Nemeth1, Conor A Bradley1, Luke Humphreys1, Izabela Stasik1, Catherine Fenning1, Joanna Majkut1, Catherine Higgins1, Nyree Crawford1, Caitriona Holohan1, Patrick G Johnston1, Timothy Harrison1, Gerard G Hanna1, Karl T Butterworth1, Kevin M Prise1, Daniel B Longley2.   

Abstract

Resistance to radiotherapy due to insufficient cancer cell death is a significant cause of treatment failure in non-small cell lung cancer (NSCLC). The endogenous caspase-8 inhibitor FLIP is a critical regulator of cell death that is frequently overexpressed in NSCLC and is an established inhibitor of apoptotic cell death induced via the extrinsic death receptor pathway. Apoptosis induced by ionizing radiation (IR) has been considered to be mediated predominantly via the intrinsic apoptotic pathway; however, we found that IR-induced apoptosis was significantly attenuated in NSCLC cells when caspase-8 was depleted using RNA interference (RNAi), suggesting involvement of the extrinsic apoptosis pathway. Moreover, overexpression of wild-type FLIP, but not a mutant form that cannot bind the critical death receptor adaptor protein FADD, also attenuated IR-induced apoptosis, confirming the importance of the extrinsic apoptotic pathway as a determinant of response to IR in NSCLC. Importantly, when FLIP protein levels were downregulated by RNAi, IR-induced cell death was significantly enhanced. The clinically relevant histone deacetylase (HDAC) inhibitors vorinostat and entinostat were subsequently found to sensitize a subset of NSCLC cell lines to IR in a manner that was dependent on their ability to suppress FLIP expression and promote activation of caspase-8. Entinostat also enhanced the antitumor activity of IR in vivo Therefore, FLIP downregulation induced by HDAC inhibitors is a potential clinical strategy to radiosensitize NSCLC and thereby improve response to radiotherapy. Overall, this study provides the first evidence that pharmacological inhibition of FLIP may improve response of NCSLC to IR. Mol Cancer Ther; 15(10); 2432-41. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27474150     DOI: 10.1158/1535-7163.MCT-16-0211

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  12 in total

1.  Pevonedistat (MLN4924): mechanism of cell death induction and therapeutic potential in colorectal cancer.

Authors:  Daniel B Longley; Victoria Coyle; Jennifer Ferris; Margarita Espona-Fiedler; Claudia Hamilton; Caitriona Holohan; Nyree Crawford; Alex J McIntyre; Jamie Z Roberts; Mark Wappett; Simon S McDade
Journal:  Cell Death Discov       Date:  2020-07-21

Review 2.  The Advances in Epigenetics for Cancer Radiotherapy.

Authors:  Yuexuan Wang; Yu Han; Yuzhen Jin; Qiang He; Zhicheng Wang
Journal:  Int J Mol Sci       Date:  2022-05-18       Impact factor: 6.208

3.  Glycogen synthase kinase-3β inhibition promotes lysosome-dependent degradation of c-FLIPL in hepatocellular carcinoma.

Authors:  Na Zhang; Xiaojia Liu; Lu Liu; Zhesong Deng; Qingxuan Zeng; Weiqiang Pang; Yang Liu; Danqing Song; Hongbin Deng
Journal:  Cell Death Dis       Date:  2018-02-14       Impact factor: 8.469

4.  Pevonedistat (MLN4924): mechanism of cell death induction and therapeutic potential in colorectal cancer.

Authors:  Daniel B Longley; Victoria Coyle; Jennifer Ferris; Margarita Espona-Fiedler; Claudia Hamilton; Caitriona Holohan; Nyree Crawford; Alex J McIntyre; Jamie Z Roberts; Mark Wappett; Simon S McDade
Journal:  Cell Death Discov       Date:  2020-07-21

5.  c-FLIP and CD95 signaling are essential for survival of renal cell carcinoma.

Authors:  Tobias Luebke; Lisa Schwarz; Yan Yan Beer; Sabrina Schumann; Maria Misterek; Frida Ewald Sander; Carlos Plaza-Sirvent; Ingo Schmitz
Journal:  Cell Death Dis       Date:  2019-05-16       Impact factor: 8.469

6.  MS-275 potentiates the effect of YM-155 in lung adenocarcinoma via survivin downregulation induced by miR-138 and miR-195.

Authors:  Bai-Ling Luo; Yan Zhou; Hui Lv; Sheng-Hua Sun; Wen-Xiang Tang
Journal:  Thorac Cancer       Date:  2019-05-14       Impact factor: 3.223

7.  Modulating the unfolded protein response with ONC201 to impact on radiation response in prostate cancer cells.

Authors:  Francesca Amoroso; Kimberley Glass; Reema Singh; Francisco Liberal; Rebecca E Steele; Sarah Maguire; Rohinton Tarapore; Joshua E Allen; Sandra Van Schaeybroeck; Karl T Butterworth; Kevin Prise; Joe M O'Sullivan; Suneil Jain; David J Waugh; Ian G Mills
Journal:  Sci Rep       Date:  2021-02-19       Impact factor: 4.379

8.  Cytoplasmic FLIP(S) and nuclear FLIP(L) mediate resistance of castrate-resistant prostate cancer to apoptosis induced by IAP antagonists.

Authors:  Christopher McCann; Nyree Crawford; Joanna Majkut; Caitriona Holohan; Chris W D Armstrong; Pamela J Maxwell; Chee Wee Ong; Melissa J LaBonte; Simon S McDade; David J Waugh; Daniel B Longley
Journal:  Cell Death Dis       Date:  2018-10-22       Impact factor: 8.469

9.  Development and Validation of Autophagy-Related Gene Signature and Nomogram for Predicting Survival in Oral Squamous Cell Carcinoma.

Authors:  Chen Hou; Hongshi Cai; Yue Zhu; Shuojin Huang; Fan Song; Jinsong Hou
Journal:  Front Oncol       Date:  2020-10-16       Impact factor: 6.244

10.  IHC-based subcellular quantification provides new insights into prognostic relevance of FLIP and procaspase-8 in non-small-cell lung cancer.

Authors:  Ryan A Hutchinson; Helen G Coleman; Kathy Gately; Vincent Young; Siobhan Nicholson; Robert Cummins; Elaine Kay; Sean O Hynes; Philip D Dunne; Seedevi Senevirathne; Peter W Hamilton; Darragh G McArt; Daniel B Longley
Journal:  Cell Death Discov       Date:  2017-08-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.